Dec 31, 2013 7:00am EST OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
Dec 30, 2013 1:00am EST OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
Dec 23, 2013 7:00am EST Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
Dec 19, 2013 7:00am EST Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
Nov 20, 2013 7:00am EST Can-Fite BioPharma Generates Partnership Interest at Therapeutic Area Partnerships Conference in Boston
